Xenon Progresses Antisense Anemia Drug In Pact With Isis
This article was originally published in The Pink Sheet Daily
Executive Summary
Private drug developer Xenon will move forward development of the novel anemia drug XEN701 for patients with chronic kidney disease and pay $2 million to partner Isis.